Health Care Businesses

Medical imaging supplier moves to Indianapolis

January 19, 2010
Scott Olson
Associated X-Ray Services relocates headquarters from South Bend to Indianapolis and also announces the company has changed its name to AXS Imaging.
More

Biotech firm plans $28M Greenwood plant

January 19, 2010
Greenwood pharmaceutical firm Elona Biotechnologies plans to build a $28 million production facility and create 70 jobs to help develop a cheaper form of insulin that could gain significant market share.
More

FDA letters scold Lilly, others over marketing materials

January 13, 2010
Associated Press
The letter to Indianapolis-based Lilly cites a print advertisement for the antidepressant Cymbalta that did not adequately display information about the drug's side effects.
More

Roche taps new local CEO

January 12, 2010
J.K. Wall
Roche Diagnostics named a new CEO for its North American operations Tuesday to replace Michael Tillmann, who resigned on Friday.
More

Tillmann out as Roche Diagnostics CEO

January 11, 2010
J.K. Wall
The management change comes as the Indianapolis company's diabetes market share has been sliding. Roche says successor will be named "shortly."
More

Hill-Rom hires new CEO

January 7, 2010
 IBJ Staff
John J. Greisch was most recently president of international operations at Baxter International Inc.
More

FDA cancels meeting to review Lilly's Cymbalta

January 5, 2010
Associated Press
The agency said the meeting was canceled "to allow time for the FDA to review new information" about a proposed new use for the drug.
More

Health care software firm RealMed regains momentum

January 2, 2010
Peter Schnitzler
RealMed enjoys a nearly 99-percent renewal rate among its current customers and attracted 4,000 new doctors in 2009. Employment at the company is rising after a steady decline.
More

Corporations bet on insiders to bend reform

December 30, 2009
J.K. Wall
Indianapolis health care heavyweights are among those spending $635 million, employing 166 former aides to key congressional leaders and committees in health reform process.
More

Health care industry braces for reform

December 26, 2009
J.K. Wall
Congress is on the cusp of transforming health insurance—if it can pass a health reform bill that was losing popularity late in the year.
More

To keep sales force busy, Lilly takes on new drug

December 24, 2009
J.K. Wall
Eli Lilly and Co. has bought the rights to co-market a new cholesterol-fighting drug in the U.S., giving it a third heart drug for sales personnel to push.
More

First Indiana Future Fund off to a slow startRestricted Content

December 19, 2009
Peter Schnitzler
More than half of the venture capital fund's original investors took a pass on its $58 million successor, the newly launched INext.
More

Setbacks in diabetes market batter Roche

December 19, 2009
J.K. Wall
Roche Diagnostics Corp., once the darling of the U.S. diabetes-device market, is now licking its wounds. And it’s mulling whether to keep fighting on all fronts or to pull back.
More

Senate rejects drug-importation proposal

December 16, 2009
 IBJ Staff and Associated Press
The U.S. Senate voted down a plan Tuesday to allow Americans to import prescriptions from abroad, handing drug makers such as Indianapolis-based Eli Lilly and Co. a victory.
More

Lilly wins approval for long-acting Zyprexa

December 14, 2009
J.K. Wall
Once-a-month injection of best-selling drug will have patents that could extend until 2018.
More

Eli Lilly's shares slip after it forecasts mixed profits in coming years

December 10, 2009
 IBJ Staff and Associated Press
The Indianapolis-based drugmaker predicts strong profits through 2011, but its forecast for 2012 suggests bottom-line results could fall precipitously.
More

Lilly launching new venture capital fund

December 10, 2009
J.K. Wall
The fund would acquire experimental drugs and use Lilly R&D staff to try to prove their effectiveness, perhaps boosting Lilly's drug pipeline.
More

Company's medical device earns expedited review

December 9, 2009
FAST Diagnostics LLC said initial human trials on its method to measure kidney function faster and more accurately than existing techniques could begin as early as next year, with commercialization following by 2012.
More

Ariad asks court to restore patent-suit win against Lilly

December 8, 2009
 IBJ Staff
A federal appeals court will decide whether Eli Lilly and Co. must pay $65.2 million in damages, plus royalties, over a drug-patent claim.
More

Part of Mississippi's Zyprexa case against Lilly dismissed

December 2, 2009
 IBJ Staff
Indianapolis-based Eli Lilly and Co. has won a bid to dismiss part of a negligence lawsuit brought by Mississippi that alleges improper marketing of antipsychotic drug Zyprexa for unapproved uses.
More

Lilly extends research pact with India firm

December 1, 2009
 IBJ Staff
Jubilant Organosys Ltd. and Indianapolis-based Eli Lilly and Co. extended their collaboration, which began in 2005, by five years.
More

Lilly's Cymbalta wins new approval for anxiety disorder

November 30, 2009
J.K. Wall
FDA action should boost sales of the Eli Lilly and Co. drug, which were already on pace to top $3 billion this year.
More

Lilly stock droops after rival claims faster-acting impotence pill

November 18, 2009
 IBJ Staff
California-based Vivus claims its drug acts in 30 minutes, compared with about 2 hours for Lilly's Cialis.
More

Arcadia sees bigger quarterly loss on lower revenue

November 16, 2009
J.K. Wall
Health care company Arcadia Resources Inc. saw growth in pharmacy business, offset by slower medical staffing sales.
More

Aarden Pharmaceuticals chose Indianapolis over San Diego for headquarters

November 14, 2009
 IBJ Staff
Thanks partly to a state grant and support from Indiana’s BioCrossroads life sciences initiative, principals “decided locating here would give Aarden a better chance of success.
More
Page  << 11 12 13 14 15 16 17 18 19 20 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Socialized medicine works great for white people in Scandanavia. It works well in Costa Rica for a population that is partly white and partly mestizo. I don't really see Obamacare as something aimed against whites. I think that is a Republican canard designed to elicit support from white people for republican candidates who don't care about them any more than democrats care about the non-whites they pander to with their phony maneuvers. But what is different between Costa Rica nd the Scandanavian nations on one hand and the US on the other? SIZE. Maybe the US is just too damn big. Maybe it just needs to be divided into smaller self governing pieces like when the old Holy Roman Empire was dismantled. Maybe we are always trying the same set of solutions for different kinds of people as if we were all the same. Oh-- I know-- that is liberal dogma, that we are all the same. Which is the most idiotic American notion going right back to the propaganda of 1776. All men are different and their differences are myriad and that which is different is not equal. The state which pretends men are all the same is going to force men to be the same. That is what America does here, that is what we do in our stupid overseas wars, that is how we destroy true diversity and true difference, and we are all as different groups of folks, feeling the pains of how capitalism is grinding us down into equally insignificant proletarian microconsumers with no other identity whether we like it or not. And the Marxists had this much right about the War of Independence: it was fundamentally a war of capitalist against feudal systems. America has been about big money since day one and whatever gets in the way is crushed. Health care is just another market and Obamacare, to the extent that it Rationalizes and makes more uniform a market which should actually be really different in nature and delivery from place to place-- well that will serve the interests of the biggest capitalist stakeholders in health care which is not Walmart for Gosh Sakes it is the INSURANCE INDUSTRY. CUI BONO Obamacare? The insurance industry. So republicans drop the delusion pro capitalist scales from your eyes this has almost nothing to do with race or "socialism" it has to do mostly with what the INSURANCE INDUSTRY wants to have happen in order to make their lives and profits easier.

  2. Read the article - the reason they can't justify staying is they have too many medicare/medicaid patients and the re-imbursements for transporting these patient is so low.

  3. I would not vote for Bayh if he did run. I also wouldn't vote for Pence. My guess is that Bayh does not have the stomach to oppose persons on the far left or far right. Also, outside of capitalizing on his time as U. S. Senator (and his wife's time as a board member to several companies) I don't know if he is willing to fight for anything. If people who claim to be in the middle walk away from fights with the right and left wing, what are we left with? Extremes. It's probably best for Bayh if he does not have the stomach for the fight but the result is no middle ground.

  4. JK - I meant that the results don't ring true. I also questioned the 10-year-old study because so much in the "health care system" has changed since the study was made. Moreover, it was hard to get to any overall conclusion or observation with the article. But....don't be defensive given my comments; I still think you do the best job of any journalist in the area shedding light and insight on important health care issues.

  5. Probably a good idea he doesn't run. I for one do not want someone who lives in VIRGINIA to be the governor. He gave it some thought, but he likes Virginia too much. What a name I cannot say on this site! The way these people think and operate amuses me.

ADVERTISEMENT